Search

Your search keyword '"Ghadyani, Mojtaba"' showing total 14 results
Start Over Author "Ghadyani, Mojtaba"
14 results on '"Ghadyani, Mojtaba"'

4. Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial

Author

Rezvani, Hamid, Mortazavizadeh, Seyed Mohammadreza, Allahyari, Abolghasem, Nekuee, Amirabbas, Najafi, Safa Najjar, Vahidfar, Mohammadreza, Ghadyani, Mojtaba, Khosravi, Adnan, Qarib, Siroos, Sadeghi, Alireza, Esfandbod, Mohsen, Rajaeinejad, Mohsen, Rezvani, Alireza, Hajiqolami, Ali, Payandeh, Mehrdad, Shazad, Babak, Anjidani, Nassim, Meskinimood, Shahab, Alikhasi, Afsaneh, Karbalaeian, Moein, and Salari, Sina

Published
2020
Full Text
View/download PDF

10. Valproic acid may exerts its cytotoxic effect through rassf1a expression induction in acute myeloid leukemia

Author

Mohammad Javad Ebrahimi, Tabarraee Mahdi, Safari Shamsi, Reyhaneh Sadat Miri-Moosavi, Sara Boosaliki, Mirfakhraie Reza, Hamid Ghaedi, Riazi-Isfahani Sahand, Ghadyani Mojtaba, Omrani Mir Davood, and Zare-Abdollahi Davood

Subjects
0301 basic medicine, Male, medicine.drug_class, Azacitidine, Decitabine, Antineoplastic Agents, Biology, Real-Time Polymerase Chain Reaction, 03 medical and health sciences, 0302 clinical medicine, medicine, Tumor Cells, Cultured, Humans, Aged, Valproic Acid, Tumor Suppressor Proteins, Histone deacetylase inhibitor, Myeloid leukemia, Induction chemotherapy, Chloroquine, Drug Synergism, General Medicine, Histone Deacetylase Inhibitors, Regimen, Leukemia, Myeloid, Acute, 030104 developmental biology, 030220 oncology & carcinogenesis, Cytarabine, Cancer research, lipids (amino acids, peptides, and proteins), Female, medicine.drug
Abstract

In acute myeloid leukemia (AML), despite the acceptance of standard intensive chemotherapy as an optimal induction regimen for all age groups, in the elderly patients, the best treatment should meet the challenge of multiple factors like age, comorbidities, and cytogenetics, making them ineligible for standard induction chemotherapy. Using the current low-intensity therapies like decitabine, azacitidine, and low-dose cytarabine as a single arm, outcomes for these patients remain poor. As a histone deacetylase inhibitor valproic acid (VPA) exhibit anticancer activity by triggering apoptosis, the mechanism of which is not yet completely clarified. To explore the possible connection between VPA treatment and the Hippo pathway as an apoptosis stimulating route, we also explore the expression of major components of this pathway and for the first time we postulate a relationship between VPA treatment and cell death induction through RASSF1A expression induction. Furthermore, we demonstrate that autophagy inhibition by chloroquine (CQ) significantly augmented the cytotoxic effect of VPA on AML cells, especially in those with unfavorable and normal karyotype. Regarding that VPA and CQ are well-tolerated drugs and our presumptive results of usefulness of VPA + CQ in three cytogenetic risk groups of AML, this combinatorial therapy could represent an attractive treatment option for older AML patients unfit for intensive therapy.

Published
2015

11. Immunotherapy in Metastatic Malignant Melanoma and Non-Small Cell Lung Cancer; a Brief Review and Position Statement from the Immuno-Oncology Clinical Forum (IOCF), Iran

Author

Tfayli, Arafat, primary, Attarian, Hamid, additional, Ghadyani, Mojtaba, additional, Ghotb, Atabak, additional, Mashadian, Mehrdad, additional, Salimi, Babak, additional, Sedaghat, Sadegh, additional, Seghatoleslami, Mohammad, additional, Seifi, Sharareh, additional, and Torabi-Nami, Mohammad, additional

Published
2016
Full Text
View/download PDF

13. Efficacy of Taxotere, Thalidomide, and Prednisolone in Patients with Hormone-Resistant Metastatic Prostate cancer.

Author

Rezvani, Hamid, Haghighi, Shirin, Ghadyani, Mojtaba, and Attarian, Hamid

Abstract

PURPOSE: To evaluate the efficacy and safety of combination treatment with thalidomide and taxotere in patients with hormone-resistant prostate cancer. MATERIALS AND METHODS: This clinical trial was performed on 16 patients with hormone-resistant prostate cancer. RESULTS: Mean age of the participants was 72.7 ± 5.39 years (range, 65 to 85 years). In 94% of patients who received the drug combination, prostate-specific antigen level decreased more than 50%. The mean time to progression was 15 months and mean survival time was 23 months. This combination therapy had some adverse events. CONCLUSION: Addition of anti-angiogenic agents, such as thalidomide, can improve therapeutic outcome in this group of patients. [ABSTRACT FROM AUTHOR]

Published
2012

14. Consolidation chemotherapy with docetaxel after platinum-based chemotherapy in patients with non-small cell lung cancer: a preliminary report.

Author

Attarian H, Rezvani H, Ghadyani M, and Eshaghi F

Abstract

Background: The efficacy of second line chemotherapy for relapsed non small cell lung cancer has been established. In this study, we evaluated the efficacy and toxicity of maintenance therapy with docetaxel in patients with non-small cell lung cancer who were stabilized with first line chemotherapy and had good performance status before relapse. The primary objective was to determine one-year survival and the other objectives were evaluation of adverse effects and time to progression., Materials and Methods: Eighteen patients with lung cancer were included in this study. All patients were at stage III and IV, without distant metastasis or neuropathy. All patients had been treated with platinum based regimen initially and were responsive or stable with no progression. The patients were treated with docetaxel 75 mg/m(2) for a total of 4 cycles repeated every 3 weeks., Results: All patients accomplished 4 chemotherapy cycles and a total of 72 cycles were administered. The mean time of progression free survival (PFS) was 9-10 months and one- year survival (OS) was 94.4% without any significant adverse effect necessitating medical intervention. The mean survival time of patients was 18 (12-20) months., Conclusion: Using docetaxel as consolidation chemotherapy in patients with non small cell lung cancer can prolong time to progression of disease and probably patients' survival without significant adverse effects or negative impact on the quality of life.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results